Summary. Currently, development of immune response to vaccines has not been studied completely; data on vaccines safety and effect on the course of chronic obstructive pulmonary disease (COPD) are lacking. Thus, vaccination against diphteria and pertussis of patients with COPD is of great importance. The aim of our study was to evaluate efficacy and safety of a vaccine against diphteria and pertussis in patients with COPD. We examined 61 moderate to severe COPD patients aged 35 to 65 years. Of them, 33 patients received the Bubo-M vaccine trice according to 0–1–6 month regimen and 28 patients received the same vaccine only once. Thirty four healthy subjects vaccinated with the same vaccine were as controls. The Bubo-M vaccine was well tolerated; no serious post-vaccine adverse events were registered. Vaccination of COPD patients did not influence the rate of acute respiratory infection episodes and did not increase the rate of acute exacerbations of COPD. A characteristic feature of immune response to the vaccine in COPD patients was slower antibody production against diphteria and pertussis anatoxins.